Combination therapy may enhance gemcitabine activity

Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer Discovery, a journal of the American Association for Cancer Research.

David Tuveson, M.D., Ph.D., a professor of pancreatic cancer medicine at the University of Cambridge, utilized a laboratory model to test the combination of and nab-paclitaxel in pancreatic cancer.

"The combination has shown promise in an early clinical trial, and clinical results from a pivotal phase III trial will be reported in 2013," said Tuveson. "However, we know very little about the mechanism of action because tumor samples have been so small."

Using a laboratory model of metastatic pancreatic , the researchers showed that combination treatment increased intratumoral gemcitabine levels due to a marked decrease in the primary gemcitabine metabolizing enzyme, cytidine deaminase.

appeared to reduce these levels through reactive oxygen species-mediated degradation, resulting in increased stabilization of gemcitabine. Tuveson said understanding these mechanisms of action are important and will lead to better administration of the therapeutic combination if the larger human trials prove positive.

"For example, we predict from this mechanistic study that nab-paclitaxel may be most effective if we administer it first, and delay administration of the gemcitabine. The next step is to test this prediction, since it could help a great deal with patient treatment," said Tuveson.

Related Stories

New drug substantially extends survival in pancreatic cancer

date Sep 16, 2008

A new form of chemotherapy that destroys new blood vessels that grow around tumors has produced excellent results in a phase II trial of patients with inoperable pancreatic cancer, researchers report at the 33rd Congress ...

Results of new drug for pancreatic cancer patients published

date Oct 04, 2011

Patients at Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare were the first in the nation to participate in a clinical trial to determine the safety, tolerability and effectiveness for usage of a new ...

Recommended for you

Study finds new potential melanoma drug target

date May 02, 2015

A new treatment for melanoma could be on the horizon, thanks to a finding by a UNC Lineberger Comprehensive Cancer Center-led team. In the study, which was published online today in the journal Clinical Ca ...

Surgery for terminal cancer patients still common

date May 02, 2015

The number of surgeries performed on terminally ill cancer patients has not dropped in recent years, despite more attention to the importance of less invasive care for these patients to relieve symptoms and ...

Study provides comprehensive look at brain cancer treatments

date May 01, 2015

Led by the Translational Genomics Research Institute (TGen) and UC San Francisco (UCSF), a comprehensive genetic review of treatment strategies for glioblastoma brain tumors was published today in the Oxford University Press ...

How artificial tanning can lead to melanoma

date May 01, 2015

Young women may be up on the latest fashions and trends as they prepare for prom season. But what many don't know is that the tan that looks oh-so-good with their dress may be the first step toward skin cancer.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.